Back to Search Start Over

Bradykinin-induced asthmatic fibroblast/myofibroblast activities via bradykinin B2 receptor and different MAPK pathways

Authors :
Leonardo M. Fabbri
Loredana Petecchia
Valentina Sorbello
Anna M. Longo
Fabio Luigi Massimo Ricciardolo
Peter J. Sterk
Antonino Di Stefano
Pieter S. Hiemstra
Giovanni A. Rossi
Fabrizio Luppi
Alessandra Eva
Federica Sabatini
Cristina Vanni
AII - Amsterdam institute for Infection and Immunity
Pulmonology
Sabatini, F
Luppi, F
Petecchia, L
Di Stefano, A
Longo, A
Eva, A
Vanni, C
Hiemstra, P
Sterk, P
Sorbello, V
Fabbri, L
Rossi, G
Ricciardolo, F
Source :
European journal of pharmacology, 710(1-3), 100-109. Elsevier, European Journal of Pharmacology, 710(1-3), 100-109
Publication Year :
2013
Publisher :
Elsevier BV, 2013.

Abstract

Bradykinin drives normal lung fibroblasts into myofibroblasts, induces fibroblast proliferation and activates mitogen activated protein kinase pathways (MAPK) but its effects on bronchial fibroblasts from asthmatics (HBAFb) have not been yet studied. We studied bradykinin-induced fibroblast proliferation and differentiation and the related intracellular mechanisms in HBAFb compared to normal bronchial fibroblasts (HNBFb). Bradykinin-stimulated HBAFb and HNBFb were used to assess: bradykinin B 2 receptor expression by Western blot analysis; cell proliferation by [ 3 H] thymidine incorporation; α-smooth muscle actin (SMA) expression/polymerization by Western blot and immunofluorescence; epidermal growth factor (EGF) receptor, extracellular-regulated kinase (ERK) 1/2 and p38 MAPK activation by immunoprecipitation and Western blot, respectively. Constitutive bradykinin B 2 receptor and α-SMA expression was higher in HBAFb as compared to HNBFb. Bradykinin increased bradykinin B 2 receptor expression in HBAFb. Bradykinin, via bradykinin B 2 receptor, significantly increased fibroblast proliferation at lower concentration (10 −11 M) and α-SMA expression/polymerization at higher concentration (10 −6 M) in both cells. Bradykinin increased ERK1/2 and p38 phosphorylation via bradykinin B 2 receptor; EGF receptor inhibitor AG1478 and panmetalloproteinase inhibitor GM6001 blocked bradykinin-induced ERK1/2 activation but not p38 phosphorylation. Bradykinin, via bradykinin B 2 receptor, induced EGF receptor phosphorylation that was suppressed by AG1478. In HBAFb AG1478, GM6001, the ERK1/2-inhibitor U0126 and the p38 inhibitor SB203580 suppressed bradykinin-induced cell proliferation, but only SB203580 reduced myofibroblast differentiation. These data indicate that bradykinin is actively involved in asthmatic bronchial fibroblast proliferation and differentiation, through MAPK pathways and EGF receptor transactivation, by which bradykinin may contribute to airway remodeling in asthma, opening new horizons for potential therapeutic implications in asthmatic patients.

Details

ISSN :
00142999
Volume :
710
Database :
OpenAIRE
Journal :
European Journal of Pharmacology
Accession number :
edsair.doi.dedup.....854f50b8be42e483c03658651ca79d5d
Full Text :
https://doi.org/10.1016/j.ejphar.2013.03.048